164 results on '"Okawa J"'
Search Results
2. Tongue pressure during swallowing liquids with different properties and volumes
3. ガム咀嚼時の舌運動と顎運動経路
4. 278 Photo validation study using cutaneous dermatomyositis disease area and severity index in dermatomyositis patients
5. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists
6. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists
7. Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis
8. Tongue movement and jaw movement path during chewing gummy jelly
9. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change
10. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone
11. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life
12. The impact of skin damage due to cutaneous lupus on quality of life*
13. POS0315 LONG-TERM SAFETY AND EFFICACY OF LENABASUM DURING 3 YEARS IN AN OPEN-LABEL EXTENSION (OLE) OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN DISEASE IN DERMATOMYOSITIS (DM)
14. 429 Spirulina use and its temporal association with dermatomyositis exacerbation
15. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score
16. 536 Comparing the Performance of Interferon Gamma Release Assays in Autoimmune Skin Diseases
17. 505 Immunostimulatory herbal supplements in patients with autoimmune skin diseases
18. Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument
19. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis
20. 610 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001
21. 568 The impact of prior authorizations for patients with complex dermatological conditions
22. The effect of thickner on tongue motion and pressure production against hard palate
23. Evaluation of CLASI by paediatric dermatologists and rheumatologists
24. 儿科皮肤病专家和风湿病专家对 CLASI 的评估
25. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists
26. FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis
27. SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001
28. Evaluation of lingual function by tongue pressure measurement and motion capture system
29. The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy
30. Effect of long-term treatment with tumour necrosis factor-α inhibitors on single-dose ultraviolet-induced changes in human skin
31. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index ( CDASI ) among dermatologists, rheumatologists and neurologists
32. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists.
33. Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis
34. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life
35. Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument
36. The cutaneous lupus erythematosus disease activity and severity index: Expansion for rheumatology and dermatology
37. Conformal light delivery using tailored cylindrical diffusers
38. Caudate blood flow and volume are reduced in HIV + neurocognitively impaired patients
39. Exploration and application of innovative TIRF microscopy.
40. Conformal light delivery using tailored cylindrical diffusers.
41. Impact of smoking in cutaneous lupus erythematosus.
42. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: Expansion for Rheumatology and Dermatology.
43. Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients.
44. The cutaneous lupus erythematosus disease activity and severity index: Expansion for rheumatology and dermatologyPresented in part at the 68th Annual Meeting of the Society of Investigative Dermatology, Los Angeles, California, May 2007.The University of Pennsylvania owns the copyright of CLASI for nonacademic use.
45. Caudate blood flow and volume are reduced in HIVneurocognitively impaired patients
46. Acute Respiratory Distress Syndrome After Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Vaccination: Findings From an Autopsy.
47. Tongue and jaw movement assessed by 3D motion capture during gum chewing.
48. Tongue pressure and maxillofacial muscle activities during swallowing in patients with mandibular prognathism.
49. Developing tongue coating status assessment using image recognition with deep learning.
50. Clinical research: photo validation study using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores in patients with dermatomyositis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.